Ascent Sued Over Proposed Copycat of ADHD Chewable (Correct)

June 23, 2021, 11:55 PM

Ascent Pharmaceuticals Inc.was accused of infringing four patents with its proposal for a generic version of Tris Pharma’s QuilliChew ER, an extended-release chewable tablet for treating Attention-Deficit/Hyperactivity Disorder in children.

  • Tris is seeking court order blocking copies until patents’ expiration in August 2033 and cash compensation if copies are made before then, according to complaint filed Tuesday in federal court in Newark, New Jersey
    • Tris also wants a judgment that Ascent’s defenses and claims for relief related to the patents “are limited to those presented in the May 10 notice letter” from Ascent to Tris about its intention to ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.